Andrea Dynder Maes
About Andrea Dynder Maes
Andrea Dynder Maes serves as the Senior Director of Biostatistics at Insmed Incorporated, bringing extensive expertise in pharmacokinetic parameter calculation and regulatory submissions. She has a strong academic background with a Ph.D. in Bioinformatics and Genetic Epidemiology from Rutgers University and has held various leadership roles in biostatistics across several pharmaceutical companies.
Current Role at Insmed
Andrea Dynder Maes serves as the Senior Director of Biostatistics at Insmed Incorporated. She has held this position since 2021. In her role, she focuses on biostatistical methodologies and contributes to the design and analysis of clinical studies, particularly in the context of pharmacokinetics and drug performance.
Previous Experience in Biostatistics
Before joining Insmed, Andrea Dynder Maes accumulated extensive experience in biostatistics across various organizations. She worked at AstraZeneca in multiple roles, including Associate Director and Director, where she led teams in biometrics and statistical analysis. Her tenure at Merck & Co., Inc. as a Senior Biometrician further solidified her expertise in the field.
Education and Expertise
Andrea Dynder Maes holds a Ph.D. in Bioinformatics and Genetic Epidemiology from Rutgers University, where she studied from 2002 to 2008. She also earned a Master of Science in Statistics from the University of Rochester and a Bachelor of Science in Psychology and Statistics from the University of Connecticut. Her educational background supports her expertise in pharmacokinetic parameter calculation and pharmacogenomics.
Regulatory Submissions and Methodological Research
Andrea Dynder Maes has successfully prepared submissions to major regulatory bodies, including the FDA, EMA, CFDA, and PMDA. She has led methodological research teams and has been involved in organization-wide training initiatives, demonstrating her leadership in biostatistical practices.
Background in Drug Studies
Andrea Dynder Maes has a strong background in designing and analyzing generic equivalence studies, particularly in the pharmacokinetics and in vitro performance of orally inhaled and nasal drug products. Her experience includes working as a Biostatistician Intern at Rhone-Poulenc Rorer and as a Senior Principal Statistician at Novartis.